Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | ALPL | P05186 | 9/20 | 0.76 |
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855912 | 0.85 | ALPL (0.76) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL2524441 | 0.85 | ALPL (0.76) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL1414008 | 0.85 | MAPT (1.00) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL646099 | 0.84 | GAA (1.00) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL1413959 | 0.84 | ALPL (1.00) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL644902 | 0.84 | MAPT (0.72) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL4788746 | 0.83 | GAA (0.75) | MAPTALPLRAB9APOLBNPC1 | |
| Hydrochloric Acid SCHEMBL1314014 | 0.83 | GAA (0.97) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL14758883 | 0.83 | MAPT (0.71) | MAPTALPLRAB9APOLBNPC1 | |
| SCHEMBL13539283 | 0.83 | ALPL (0.73) | MAPTALPLRAB9APOLBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479806-B | D-amino acid oxidase inhibitors and therapeutic uses thereof | 心悦生医股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111479806-A | D-amino acid oxidase inhibitors and therapeutic uses thereof | 心悦生医股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| US-8119693-B2 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | MAPT 3950/4885ALPL 1/4885RAB9A 3655/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | MAPT 3950/4885ALPL 1/4885RAB9A 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.